To view this email as a web page, click here.

Does Dabrafenib Plus Trametinib Offer Survival Benefit in Metastatic Melanoma?

A pooled analysis included extended-survival data from COMBI-d and COMBI-v trials, both of which included treatment-naïve patients with unresectable or metastatic melanoma who were randomized to receive either dabrafenib plus trametinib or BRAF inhibitor monotherapy.

A 23-Year-Old Man With Calf Pain

A 23-year-old young man presents with pain in his left calf. A physical examination detects a mass in the calf area. What is your diagnosis?

IN CASE YOU MISSED IT

Quiz: Incidence and Screening in Prostate Cancer

How much do you know about the incidence and screening of prostate cancer? Here's your chance to find out.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.